Practical Therapeutics

AIDS and Other Manifestations of HIV Infection

Volumn , Issue , 2004, Pages 913-930

  Piscitelli, Stephen C ^a   Penzak, Scott R ^b   Flexner, Charles ^b  

^a GLAXOSMITHKLINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84942935023     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012764051-8/50038-X     Document Type: Chapter

References (148)

1. Knupp CA, Milbrath R, Barbhaiya RH Effect of time of food administration on the bioavailability of didanosine from a chewable tablet formulation. J Clin Pharmacol 1993, 33:568.
2. Videx EC (didanosine) product monograph 2001, Bristol Myers-Squibb, Princeton, NJ.
3. Unadkat JD, Collier AC, Crosby SS, et al. Pharmacokinetics of oral zidovudine (azidothymidine) in patients with AIDS when administered with and without a high-fat meal. AIDS 1990, 4:299.
4. Sahai J, Gallicano K, Garber G, et al. The effect of a protein meal on zidovudine pharmacokinetics in HIV-infected patients. Br J Clin Pharmacol 1992, 33:657.
5. Flexner C HIV protease inhibitors. N Engl J Med 1998, 338:1281.
6. Flexner C Dual protease inhibitor therapy in HIV-infected patients: pharmacologic rationale and clinical benefits. Annu Rev Pharmacol Toxicol 2000, 40:649-674.
7. Lea AP, Faulds D Ritonavir. Drugs 1996, 52:541.
8. Smith PF, DiCenzo, Morse GD Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors. Clin Pharmacokinet 2001, 40:893-905.
9. Sustiva (efavirenz) product monograph 2000, DuPont Pharmaceuticals, Wilmington, DE.
10. Rescriptor (delavirdine) product monograph 1997, Pharmacia & Upjohn, Kalamazoo, MI.
11. Blaschke T, Flexner C, Sheiner L, et al. Effect of simultaneous or staggered dosing of saquinavir, ritonavir, and nelfinavir on pharmacokinetic interactions. Program and Abstracts of the 7th Conference on Retroviruses and Opportunistic Infections 2000, (Abst. 76).
12. Saah A, Winchell M, Seniuk M, Nessly M, Deutsch P Multiple-dose pharmacokinetics (PK) and tolerability of indinavir (IDV) and ritonavir (RTV) combinations in a once-daily regimen in healthy volunteers (Merck 089). Program and Abstracts from the 39th ICAAC 1999, (Abst. 329).
13. Kilby JM, Sfakianos G, Gizzi N, Siemon-Hryczyk P, Ehrensing E, Oo C, Buss N, Saag MS Safety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus minidose ritonavir in human immunodeficiency virus-negative adults. Antimicrob Agents Chemother 2000, 44:2672.
14. Piscitelli SC, Gallicano KD Interactions among drugs for HIV and opportunistic infections. N Engl J Med 2001, 344:984.
15. Retrovir (zidovudine) product monograph 2000, GlaxoSmithKline, Research Triangle Park, NC.
16. Hivid (zalcitabine) product monograph 1994, Roche Laboratories, Nutley, NJ.
17. Zerit (stavudine) product monograph 1994, Bristol Myers-Squibb, Princeton, NJ.
18. Epivir (lamivudine) product monograph 2000, Glaxo Smith Kline, Research Triangle Park, NC.
19. Fortovase (saquinavir) product monograph 1997, Roche Laboratories, Nutley, NJ.
20. Norvir (ritonavir) product monograph 1996, Abbott Laboratories, Abbott Park, IL.
21. Crixivan (indinavir) product monograph 1996, Merck & Co., West Point, PA.
22. Viracept (nelfinavir) product monograph 1997, Agouron Pharmaceuticals, La Jolla, CA.
23. Viramune (nevirapine) product monograph 1996, Roxanne Laboratories, Columbus, OH.
24. Agenerase (amprenavir) product monograph 2000, Glaxo Smith Kline, Research Triangle Park, NC.
25. Kaletra (lopinavir-ritonavir) product monograph 2001, Abbott Laboratories, Abbott Park, IL.
26. Abacavir (Ziagen) product monograph 2000, Glaxo Smith Kline, Research Triangle Park, NC.
27. Viread (Tenofovir) product monograph 2002.
28. Polk RE Drug-drug interactions with ciprofloxacin and other fluoroquinolones. Am J Med 1989, 87(Suppl 5A):8776S.
29. Noyes M, Polk RE Norfloxacin and absorption of magnesium-aluminum. Ann Intern Med 1988, 109:168.
30. Lehto P, Kivisto KT Effect of sucralfate on absorption of norfloxacin and ofloxacin. Antimicrob Agents Chemother 1994, 38:248.
31. Sahai J, Gallicano K, Oliveras RT, et al. Cations in the didanosine tablet reduce ciprofloxacin bioavailability. Clin Pharmacol Ther 1993, 53:292.
32. Piscitelli SC, Goss TF, Wilton JH, et al. Effects of ranitidine and sucralfate on ketoconazole bioavailability. Antimicrob Agents Chemother 1991, 35:1765.
33. Lake-Bakaar G, Tom W, Lake-Bakaar D, et al. Gastropathy and ketoconazole malabsorption in the acquired immunodeficiency syndrome. Ann Intern Med 1988, 109:471.
34. Van Der Meer JWM, Keuning JJ, Scheijgrond HW, et al. The influence of gastric acidity on the bio-availability of ketoconazole. J Antimicrob Chemother 1980, 6:552.
35. Blum RA, D'Andrea DT, Florentino BM, et al. Increased gastric pH and the bioavailability of fluconazole and ketoconazole. Ann Intern Med 1991, 114:755.
36. Lange D, Pavao JH, Wu J, et al. Effect of a cola beverage on the bioavailability of itraconazole in the presence of H2 blockers. J Clin Pharmacol 1997, 37:535.
37. Penzak SR, Gubbins PO, Gurley BJ, Wang PL, Saccente M Grapefruit juice decreases the systemic availability of itraconazole capsules in healthy volunteers. Ther Drug Monit 1999, 21:304-309.
38. Kawakami M, Suzuki K, Ishizuka T, Hidaka T, Matsuki Y, Nakamura H Effect of grapefruit juice on pharmacokinetics of itraconazole in healthy subjects. Int J Clin Pharmacol Ther 1998, 36(6):306-308. Jun.
39. Van de Velde VJ, Van Peer AP, Heykants JJ, et al. Effect of food on the pharmacokinetics of a new hydroxypropyl-betacyclodextrin formulation of itraconazole. Pharmacotherapy 1996, 16:424.
40. Benet LZ, Kroetz DL, Sheiner LB Pharmacokinetics: dynamics of drug absorption, distribution, and elimination. The pharmacological basis of therapeutics 1996, McGraw-Hill, New York. 9th ed. J.G. Hardman, L.E. Limbird (Eds.).
41. Kolars JC, Lown KS, Schmiedlin-Ren P, et al. CYP3A gene expression in human gut epithelium. Pharmacogenetics 1994, 4:247-259.
42. Kane GC, Lipsky JJ Drug-grapefruit juice interactions. Mayo Clin Proc 2000, 75:933-942.
43. Shelton MJ, Wynn HE, Hewitt RG, DiFrancesco R Effects of grapefruit juice on pharmacokinetic exposure to indinavir in HIV-positive subjects. J Clin Pharmacol 2001, 41:435-442.
44. Penzak SR, Acosta EP, Edwards DJ, Hon YY, Desai HD, Jann MW Effect of Seville Orange Juice and Grapefruit Juice on Indinavir Pharmacokinetics in Healthy Volunteers. Programs and Abstracts of the 41st Interscience Conference of Antimicrobial Agents and Chemotherapy 2001, A-488. Chicago, ILL.
45. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I Expression of multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 1987, 84:265-269.
46. Chaudhary PM, Roninson IB Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 1991, 66:85-94.
47. Khaliq Y, Gallicano K, Venance S, et al. Effect of ketoconazole on ritonavir and saquinavir concentrations in plasma and cerebrospinal fluid from patients infected with human immunodeficiency virus. Clin Pharmacol Ther 2000, 68:637-646.
48. Lee CG, Ramachandra M, Jeang KT Effect of ABC transporters on HIV-1 infection: inhibition of virus production by the MDR1 transporter. FASEB J 2000, 14:516-522.
49. Flexner C, Speck RR Role of multidrug transporters in HIV pathogenesis. Eighth Conference on Retroviruses and Opportunistic Infections 2001, (Abstr S4).
50. Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP, Decosterd LA, Furrer H, Opravil M, Pantaleo G, Rotelska D, Ruiz L, Schinkel AH, Vernazza P, Eap CB, Telenti A, the Swiss HIV Cohort Study Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 2002, 359:30-36.
51. Kim RB, Wandel C, Leake B, et al. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res 1999, 16:408-414.
52. Centers for Disease Control and Prevention: Clinical update: impact on HIV protease inhibitors on the treatment of HIV-infected tuberculosis patients with rifampin. MMWR 2000, 49:185-189.
53. Hamzeh F, Benson C, Gerber J, Currier J, McCrea J, Deutsch P, Ruan P, Wu H, Lee L, Flexner C Steady-state pharmacokinetic interaction of modified-dose indinavir and rifabutin. Eighth Conference on Retroviruses and Opportunistic Infections 2001, (Abst 742).
54. Benedek I, Joshi A, Fiske WD, White SJ, Stevenson D, Bawerjee G, Kornhauser DM Pharmacokinetic interaction between efavirenz (EFZ) and rifampin (RIF) in healthy volunteers. 12th World AIDS Conference Geneva 1998, (42280).
55. Murphy R, Gagnier P, Lamson M, et al. Effect of nevirapine on pharmacokinetics of indinavir and ritonavir in HIV-1 patients. Program and Abstracts of the 4th Conference on Retroviruses and Opportunistic Infections 1997, 374. (Abst No. 374), Westover Management Group, Alexandria, VA.
56. Sahai J, Cameron W, Salgo M, et al. Drug interaction between saquinavir and nevirapine. Program and Abstracts of the 4th Conference on Retroviruses and Opportunistic Infections 1997, (Abstr No. 614), Westover Management Group, Alexandria, VA.
57. Barry M, Mulcahy F, Merry C Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. Clin Pharmacokinet 1999, 36:289-304.
58. Ouellet D, Hsu A, Qian J, et al. Effect of ritonavir on the pharmacokinetics of ethinyl estradiol in healthy female volunteers. Program and Abstracts of the XIth International Conference on AIDS 1996, (Abst No. Mo.B.1198).
59. Hsu A, Granneman GR, Witt G, et al. Assessment of multiple doses of ritonavir on the pharmacokinetics of theophylline. Program and Abstracts of the XIth International Conference on AIDS 1996, (Abst No. Mo.B.1200).
60. Penzak SR, Lawhorn WD, Hon YY, Shirley KL, Jann MW Influence of Ritonavir and CYP1A2 Genotype on Olanzapine Disposition in Healthy Subjects. Programs and Abstracts of the 41st Interscience Conference of Antimicrobial Agents and Chemotherapy 2001, A-493. Chicago, ILL.
61. Cato A, Cavanaugh JH, Shi H, et al. Assessment of multiple doses of ritonavir on the pharmacokinetics of rifabutin. Program and Abstracts of the XIth International Conference on AIDS 1996, (Abstr No. Mo.B.175).
62. Sun E, Heath-Chiozzi M, Cameron DW, et al. Concurrent ritonavir and rifabutin increases the risk of rifabutin-associated adverse effects. Program and Abstracts of the XIth International Conference on AIDS 1996, (Abstr No. Mo.B.171).
63. Ouellet D, Hsu A, Granneman GR, et al. Assessment of the pharmacokinetic interaction between ritonavir and clarithromycin (abstract). Clin Pharmacol Ther 1996, 59:143.
64. Honig PK, Wortham DC, Zamani K, et al. Comparison of the effects of the macrolide antibiotics erythromycin, clarithromycin, and azithromycin on terfenadine steady-state pharmacokinetics and electrocardiographic parameters. Drug Invest 1994, 7:148.
65. Paris DG, Parente TF, Bruschetta HR, et al. Torsades de pointes induced by erythromycin and terfenadine. Am J Emerg Med 1994, 12:636.
66. Hsu A, Granneman GR, Cao G, Carothers L, el-Shourbagy T, Baroldi P, Erdman K, Brown F, Sun E, Leonard JM Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir. Clin Pharmacol Ther 1998, 63:453-464.
67. Hsu A, Granneman GR, Witt G, et al. Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother 1997, 41:898-905.
68. Hsu A, Granneman GR, Bertz RJ Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet 1998, 35:275.
69. Kilby M, Hill AM, Buss N The effect of ritonavir on increases in saquinavir plasma concentration is independent of ritonavir dosage: combined analysis of 120 subjects. Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy 2000, (Abstr 1650).
70. Drewe J, Gutmann H, Fricker G, Török M, Beglinger C, Huwyler J HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833. Biochem Pharmacol 1999, 57:1147-1152.
71. Hsu A, Granneman GR, Cao G, et al. Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers. Antimicrob Agents Chemother 1998, 42:2784-2791.
72. Saah AJ, Winchell G, Seniuk M, Deutsch P Multiple-dose pharmacokinetics and tolerability of indinavir ritonavir combinations in healthy volunteers. Program and Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections 1999, 136. (Abstr).
73. Lin JH Role of pharmacokinetics in the discovery and development of indinavir. Adv Drug Del Rev 1999, 39:33-49.
74. Burger D, Felderhof M, Phanupak P, et al. Both short-term virological efficacy and drug-associated nephrotoxicity are related to indinavir (IDV) pharmacokinetics in HIV-1 infected Thai patients. Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections 2001, (Abst 730).
75. Lamotte C, Peytavin G, Perre P, et al. Increasing adverse events (AE) with indinavir (IDV) dosages and plasma concentrations in four different ritonavir (RTV)-IDV containing regimens in HIV-infected patients. Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections 2001, (Abst 738).
76. Burger D, Felderhof M, Phanupak P, et al. Pharmacokinetic-pharmacodynamic relationships in HIV-1 infected Thai patients using indinavir 800 mg + ritonavir 100 mg q 12h. Program and Abstracts of the 2nd Workshop on Clinical Pharmacology of HIV Therapy 2001, Noordwijk, The Netherlands (Abstr 5.12).
77. Workman C, Whittaker W, Dyer W, Sullivan J Combining ritonavir and indinavir decreases indinavir-associated nephrolithiasis. Program and Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections 1999, 195. (Abstr).
78. Anderson PL, Brundage RC, Kakuda TN, Fletcher CV Indinavir (IDV) maximum plasma concentration (Cmax) predicts CD4+ response in persons with highly suppressed HIV-RNA. Program and Abstracts of the 8th Conference on Retroviruses and Opportunistic Infections 2001, Chicago, Illinois (Abstr 731).
79. Aarnoutse RE, Burger DM, Hugen WH, Telg TD, Grintjes KJT, Koopmans PP, Stek M, Reiss P, Lange JMA, Hekster YA P pharmacokinetic (PK) study to investigate the influence of efavirenz (EFZ) on a BID indinavir (IDV)/ritonavir (RTV) regimen (800. 100 mg) in healthy volunteers. Programs and Abstracts of the 40th Interscience Conference of Antimicrobial Agents and Chemotherapy 2000, Toronto, Canada (Abst 423).
80. Hurst M, Faulds D Lopinavir. Drugs 2000, 60:1371-1379.
81. Bertz R, Lam W, Brun S, et al. Multiple-dose pharmacokinetics of ABT-378/ritonavir in HIV+ subjects. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy 1999, (Abst 327).
82. Gulick R, King M, Brun S, et al. ABT-378/Ritonavir in anti-retroviral naïve HIV+ patients: 72 weeks. 7th Conference on Retroviruses and Opportunistic Infections 2000, (Abst 515).
83. Bertz R, Lam W, Hsu A, et al. Assessment of the pharmacokinetic interaction between ABT-378/ ritonavir and efavirenz in healthy volunteers and in HIV+ subjects. Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy 2000, (Abstr 424).
84. Piscitelli S, Bechtel C, Sadler B, Falloon J The addition of a second protease inhibitor eliminated amprenavir-efavirenz interactions and increase amprenavir concentrations. 7th Conference on Retroviruses and Opportunistic Infections 2000, 90. (Abst).
85. Sadler BM, Piliero P, Preston SL, et al. Pharmacokinetic drug interaction between amprenavir and ritonavir in HIV seronegative subjects after multiple, oral dosing. Program and Abstracts of the 7th Conference on Retroviruses and Opportunistic Infections 2000, San Francisco, CA (Abst 77).
86. Degen O, Kurowski M, Van Lunzen J, Schewe CK, Stellbrink H-J Amprenavir (APV) and ritonavir (RTV): intraindividual comparison of different doses and influence of concomitant NNRTI on steady-state pharmacokinetics in HIV-infected patients. Program and Abstracts of the 8th Conference on Retroviruses and Opportunistic Infections 2001, Chicago, Illinois (Abst 739).
87. Wood R, Trepo C, Livrozet JM, Arasteh K, Eron J, Kaur P, Naderer O, Wire MB Amprenavir (APV) 600 mg/Ritonavir (RTV) 100 mg BID or APV 1200 mg/RTV 200 mg QD Given in Combination with Abacavir (ABC) and Lamivudine (3TC) Maintains Efficacy in ART- Naive HIV-1-Infected Adults over 12 Weeks (APV20001). Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections 2001, Chicago, Illinois (Abstr 332).
88. Flexner C, Hsu A, Kerr B, Gallant J, Heath-Chiozzi M, Anderson R Steady-state pharmacokinetic interactions between ritonavir (RTV), nelfinavir (NFV), and the nelfinavir active metabolite M8 (AG1402). Twelfth World AIDS Conference 1998.
89. Zhang KE, Wu E, Patick AK, Kerr B, Zorbas M, Lankford A, Kobayashi T, Maeda Y, Shetty B, Webber S Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma, and antiviral activities. Antimicrob Agents Chemother 2001, 45:1086.
90. Kurowski M, Kaeser B, Mroziekiewicz A, et al. The influence of low doses of ritonavir on the pharmacokinetics of nelfinavir 1250 mg twice daily. Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy 2000, (Abstr 1639).
91. Kravcik S, Sahai J, Kerr B, et al. Nelfinavir mesylate increases saquinavir soft gel capsule exposure in HIV + patients. Program and Abstracts of the 4th Conference on Retroviruses and Opportunistic Infections 1997, (Abstr No. 371), Westover Management Group, Alexandria, VA.
92. Piroth L, Grappin M, Buisson M, et al. Randomized salvage therapy with saquinavir-ritonavir versus saquinavir-nelfinavir for highly experienced HIV-infected patients. Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy 2000, (Abstr 543).
93. Havlir DV, Riddler S, Squires K, et al. Coadministration of indinavir (IDV) and nelfinavir (NFV) in a twice daily regimen: Preliminary safety, pharmacokinetic and anti-viral activity results. Program and Abstracts of 5th Conference on Retroviruses and Opportunistic Infections 1998, (Abstr 393).
94. Merrill DP, Manion DJ, Chou TC, Hirsch MS Antagonism between human immunodeficiency virus type 1 protease inhibitors indinavir and saquinavir in vitro. J Infect Dis 1997, 176:265-268.
95. Meynard JL, Poirier JM, Guiard-Schmid JB, Morand-Joubert L, Jacquemet N, Rozenbaum W, Jaillon P Impact of ABT 378/r on the amprenavir (APV) plasma concentration in HIV-experienced patients treated by the association APV - ABT 378/r. Programs and Abstracts of the 41st Interscience Conference of Antimicrobial Agents and Chemotherapy 2001, Chicago, ILL. I-1736.
96. Cox SR, Ferry JJ, Batts DH, et al. Delavirdine and marketed protease inhibitors: pharmacokinetic interaction studies in healthy volunteers. Program and Abstracts of the 4th Conference on Retroviruses and Opportunistic Infections 1997, (Abst No. 372), Westover Management Group, Alexandria, VA.
97. Cox SR, Schneck BD, Herman BD, et al. Delavirdine and nelfinavir: a pharmacokinetic drug interaction study in healthy adult volunteers. Program and Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections 1998, (Abstr No. 345), Westover Management Group, Alexandria, VA.
98. Grub S, Bryson H, Goggin T, Lüdin E, Jorga K The interaction of saquinavir (soft gelatin Capsule) with ketoconazole, erythromycin and rifampicin: comparison of the effect in healthy volunteers and in HIV-infected patients. Eur J Clin Pharmacol 2001, 57:115-121.
99. Cardiello P, Kroon E, Hoetelmans R, et al. Steady-state pharmacokinetics (PK) of saquinavir (SQV) with and without two doses of itraconazole in HIV-1 + Thai patients. HIV NATOO1.2 substudy. 13th International AIDS Conference 2000, (Abstr WeorB545).
100. Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J St. John's wort and indinavir concentrations. Lancet 2000, 355:547-548.
101. de Maat MMR, Hoetelmans RMW, Mathot RAA, van Gorp ECM, Meenhorst PL, Mulder JW, Beijnen JH Drug Interaction between St. John's wort and nevirapine. AIDS 2001, 15:420-421.
102. Roby CA, Anderson GD, Kantor E, Dryer DA, Burstein AH St John's Wort: effect on CYP3A4 activity. Clin Pharmacol Ther 2000, 67:451-457.
103. Johne A, Brockmoller J, Bauer S, Maurer A, Langheinrich M, Roots I Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum). Clin Pharmacol Ther 1999, 66:338-345.
104. Laroche M, Choudhri S, Gallicano K, Foster B Severe gastrointestinal toxicity with concomitant ingestion of ritonavir and garlic. Can J Infect Dis 1998, 9(suppl A):471P. (Abst).
105. Piscitelli SC, Burstein AH, Welden N, et al. Garlic supplements decrease plasma saquinavir concentrations. Program and Abstracts of the 8th Conference on Retroviruses and Opportunistic Infections 2001, Chicago, Illinois (Abst 743).
106. Piscitelli SC, Formentini E, Burstein AH, et al. The effect of milk thistle on the pharmacokinetics of indinavir in healthy volunteers. Pharmacotherapy 2002, (in press).
107. Piscitelli SC Use of complementary medicines by patients with HIV infection: Full sail into uncharted waters 2000, www.medscape.com, May.
108. Reiss WG, Piscitelli SC Drug-cytokine interactions: mechanisms and clinical implications. BioDrugs 1998, 9:389-395.
109. Piscitelli SC, Vogel S, Figg WD, et al. Alteration in indinavir clearance during interleukin-2 infusions in HIV-infected patients. Pharmacotherapy 1998, 18:1212-1216.
110. Elkahwaji J, Robin MA, Berson A, Tinel M, Lettéron, Labbe G, Beaune P, Elias D, Rougier P, Escudier B, Duvillard P, Pessayre B Decrease in hepatic cytochrome P450 after interleukin-2 immunotherapy. Biochem Pharmacol 1999, 57:951-954.
111. Moore KHP, Yuen GJ, Raasch RH, et al. Pharmacokinetics of lamivudine administered alone and with trimethoprim sulfamethoxazole. Clin Pharmacol Ther 1996, 59:550.
112. Laskin OL, De Miranda P, King DH, et al. Effects of probenecid on the pharmacokinetics and elimination of acyclovir in humans. Antimicrob Agents Chemother 1982, 21:804.
113. Flaherty J, JKearney B, Wolf J, Sayre J, Barriere S, Wong S, Wulfsohn M, Coakley D Coadministration of tenofovir DF (TDF) and didanosine (ddI): a pharmacokinetic (PK) and safety evaluation. Programs and Abstracts of the 41st Interscience Conference of Antimicrobial Agents and Chemotherapy 2001, I-1729. Chicago, ILL.
114. Sim SM, Hoggard PG, Sales SD, et al. Effect of ribavirin on zidovudine efficacy and toxicity in vitro: concentration-dependent interaction. AIDS Res Hum Retroviruses 1998, 14:1661-1667.
115. Back D, Haworth S, Hoggard P, Khoo S, Barry M Drug interactions with d4T phosphorylation in vitro. Program and Abstracts of the XI International Conference on AIDS 1996, 88. (Abstr).
116. Havlir DV, Friedland G, Pollard R, et al. Combination zidovudine and stavudine therapy versus other nucleosides: report of two randomized trials (ACTG 290 and 298). 5th Conference on Retroviruses and Opportunistic Infections 1998, 79. (Abstr).
117. Veal GJ, Hoggard PG, Barry MG, Khoo S, Back DJ Interaction between lamivudine and other nucleoside analogs for intracellular phosphorylation. AIDS 1996, 10:546.
118. Garraffo R, Demarles D, Durant J, Rahelinirina V, Clevenbergh P, Ceppi C, Serini M, Bidault R, Dellamonica P Amprenavir (AMP) plasma and intracellular concentrations when coadministered with ritonavir (RTV) in twice and once daily regimen in HIV-infected patients. Programs and Abstracts of the 41st Interscience Conference of Antimicrobial Agents and Chemotherapy 2001, Chicago, ILL. A-489.
119. Pollard RB, Peterson D, Hardy D, Pottage J, Murphy RL, Gathe J, Beall G, Rutkievicz V, Reynolds L, Cross AP, Dunkle LM Safety and antiretroviral effects of combined didanosine and stavudine therapy in HIV-infected individuals with CD4 counts of 200 to 500 cells/mm3. J Acquir Immune Defic Syndr 1999, 22:39.
120. Evans L, Spelman M The problem of noncompliance with drug therapy. Drugs 1983, 25:63.
121. Cramer JA, Mattson RH, Prevey ML, et al. How often is medication taken as prescribed? A novel assessment technique. JAMA 1989, 261:3723.
122. Chesney MA Factors affecting adherence to antiretroviral therapy. Clin Infect Dis 2000, (Suppl. 2):S171-S176. Jun 30.
123. Flexner C, Noe D, Benson C, Currier J, Andrade A, Shaver A Adherence patterns in patients with symptomatic Mycobacterium avium complex (MAC) infection taking a twice-daily clarithromycin regimen. Int Conf AIDS 1998, 12:585. (Abst No. 32324), ACTG 223 Study TeamACTG 223 Study Team.
124. Kasstrisios H, Flowers NT, Suarez JR, et al. Assessment of differential compliance in ACTA Protocol 175 (abstract). Clin Pharmacol Ther 1994, 55:191.
125. Kasstrisios H, Flowers NT, Blaschke TF Introducing medical students to medication noncompliance. Clin Pharmacol Ther 1996, 59:577.
126. Rudd P, Byyny RL, Zachary V, et al. The natural history of medication compliance in a drug trial: limitations of pill counts. Clin Pharmacol Ther 1989, 46:169.
127. Waterhouse DM, Calzone KA, Mele C, et al. Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring. J Clin Oncol 1993, 11:1189.
128. Cramer JA, Spilker B Patient compliance in medical practice and clinical trials 1991, Raven Press, New York.
129. Bangsberg DR, Perry S, Charlebois ED, Karasic DH, Sorensen JL, Clark RA, Dilley JW, Moss AR Depression symptoms (DS) predict HAART adherence, duration, unstructured treatment interruption and viral suppression. Programs and Abstracts of the 41st Interscience Conference of Antimicrobial Agents and Chemotherapy 2001, Chicago, ILL. I-1721.
130. Lucas GM, Cheever LW, Chaisson RE, Moore RD Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr 2001, 27:251-259.
131. Vanhove GF, Schapiro JM, Winters MA, et al. Patient compliance and drug failure in protease inhibitor monotherapy (letter). JAMA 1996, 276:1955.
132. Bangsberg DR, Hecht FM, Charlebois ED, Zolopa AR, Holodniy M, Sheiner L, Bamberger JD, Chesney MA, Moss A Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 2000, 14(4):357-366. Mar 10.
133. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, Wagener MM, Singh N Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000, 133(1):21-30. Jul 4.
134. Schapiro JM, Winters MA, Stewart F, et al. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Ann Intern Med 1996, 124:1039-1050.
135. Molla A, Korneyeva M, Gao Q, et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nature Med 1996, 2:760-766.
136. Stein DS, Fish DG, Bilello JA, et al. A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir). AIDS 1996, 10:485-492.
137. Burger DM, Hoetelmans RMW, Mulder JW, et al. Low plasma levels of indinavir (IDV) are highly predictive of virological treatment failure in patients using IDV-containing triple therapy (Abstract 42275). 12th World AIDS Conference 1998.
138. Pithavala Y, Zhang M, Knowles M, et al. Virologic response-plasma concentration relationship in phase III study of nelfinavir mesylate (Abstract 12304). 12th World AIDS Conference 1998.
139. Lorenzi P, Yerly S, Abderrakim K, et al. Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with advanced HIV infection treated with ritonavir and saquinavir. AIDS 1997, 11:F95-F99.
140. Acosta EP, Henry K, Weller D, et al. Indinavir pharmacokinetics and relationships between exposure and antiviral effect. Pharmacotherapy 1999, 19:708-712.
141. Fletcher CV, Fenton T, Powell C, et al. Pharmacologic characteristics of efavirenz and nelfinavir associated with virologic response in HIV-infected children. Program and Abstracts of the 8th Conference on Retroviruses and Opportunistic Infections 2001, Chicago, Illinois (Abstr 259).
142. Burger DM, Hugen PWH, Droste J, et al. Therapeutic drug monitoring of indinavir in treatment naïve patients improves therapeutic outcome after 1 year: results from ATHENA. 2nd International Workshop on Clinical Pharmacology of HIV Therapy 2001, (Abstr 6.2a).
143. Burger DM, Hugen PWH, Droste J, et al. Therapeutic drug monitoring of nelfinavir 1250 bid in treatment naïve patients improves therapeutic outcome after 1 year: results from ATHENA. 2nd International Workshop on Clinical Pharmacology of HIV Therapy 2001, (Abstr 6.2b).
144. Clevenbergh P, Durant J, Garraffo R, et al. Usefulness of protease inhibitor therapeutic drug monitoring? PharmAdapt: A prospective multicentric randomized controlled trial: 12 week results. 8th Conference on Retroviruses and Opportunistic Infection 2001, (Abstr 260B).
145. Kempf D, Hsu A, Jiang P, et al. Response to ritonavir intensification in indinavir recipients is highly correlated with inhibitory quotient. Program and Abstracts of the 8th Conference on Retroviruses and Opportunistic Infections 2001, Chicago, Illinois (Abstr 523).
146. Kempf D, Hsu A, Isaacson J, et al. Evaluation of the inhibitory quotient as a pharmacodynamic predictor of the virologic response to protease inhibitor therapy. 2nd International Workshop on Clinical Pharmacology of HIV Therapy 2001, (Abst 7.3).
147. Fletcher CV, Anderson PL, Kakuda TN, et al. A novel approach to integrate pharmacologic and virologic characteristics: an in vivo potency index for antiretroviral agents. Program and Abstracts of the 8th Conference on Retroviruses and Opportunistic Infections 2001, Chicago, Illinois (Abst 732).
148. U.S.PDI Drug Information in Lay Language 1996, The United States Pharmacopoeia Convention, Inc.